ArticleMolecular biology reports2026
Preliminary miRNA profiling of plasma from patients infected with distinct SARS-CoV-2 variants.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundEpigenetic regulation can play a dual role in viral infection, acting as part of the host defense, while being hijacked to control viral latency, replication, and persistence. During the COVID-19 pandemic, substantial evidence indicated that different SARS-CoV-2 variants may lead to distinct outcomes by affecting different molecular pathways, including epigenetic mechanisms. METHODS AND
resultsIn this study, we assessed miRNA expression using high-throughput microarray technology to simultaneously measure the expression of thousands of miRNAs. We focused on: comparing Delta and Omicron infections with healthy controls; identifying specific miRNAs linked to symptom severity; analyzing miRNA expression across different stages of Delta variant infection; and predicting miRNA target genes and evaluating miRNA-mRNA interactions. We identified 65 miRNAs that were significantly differentially expressed simultaneously in both SARS-CoV-2 variants compared to healthy samples. These miRNAs were categorized into distinct functional groups based on their roles in viral infection. We observed an association between the expression of specific miRNAs and virus-induced symptom severity and patients' outcomes in both variants. Furthermore, we examined miRNA expression across the various phases of the Delta variant and identified 38 miRNAs that were significantly differentially expressed. Finally, mRNA-miRNA interaction analysis revealed PTEN, IGF1R, MYC, and STAT3 as the most interacting genes.
conclusionProfiling thousands of miRNAs in response to different SARS-CoV-2 variants offers new opportunities for diagnosis, prognosis, and therapy. Although comorbidities and pathway cross-talk may influence the obtained results, our findings provide novel insights into the host response to SARS-CoV-2 infection at the epigenetic level.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.